Our answer
Telehealth is still a good business going into 2027 if you start with a specific patient group, a clinical partner and a fixed-cost structure that breaks even at a few dozen patients. It is a poor business if your plan is generic GLP-1 prescriptions sold through paid social at a low price, because three public companies and three retailers already sell that.
The evidence from the last four weeks backs both halves. Rock Health's Q3 report, published October 12, counted $3.7 billion raised across 114 deals in the quarter and $11.1 billion across 358 deals year to date, with 164 M&A transactions so far in 2026. Over the same months, the biggest cash-pay brand saw its gross margin fall twelve points and the biggest cash-pay therapy brand shrank.
The scorecard
| Signal | Latest number | Source and date | Reads as |
|---|---|---|---|
| Venture funding, Q3 2026 | $3.7B across 114 deals (Q3 2025: $3.5B, 107) | Rock Health, Oct 12 | Flat to slightly up |
| Venture funding, year to date | $11.1B across 358 deals | Rock Health, Oct 12 | On pace with 2025 |
| Concentration | 20 rounds of $100M+ took 45% of H1 dollars | Rock Health H1 report | Big checks go to few companies |
| M&A | 45 deals in Q3, 164 year to date | Rock Health, Oct 12 | Active buyers |
| Hims & Hers Q2 | Revenue $753.2M (+38%); gross margin 64%, from 76% | Q2 release, Aug 2026 | Growth at lower margin |
| LifeMD Q2 | Revenue $47.3M (from $49.0M); gross margin about 89% | Q2 release, Aug 5 | Margin held, top line shrank |
| BetterHelp Q2 | Revenue $212.6M, down 12% | Teladoc Q2 release, Jul 2026 | Cash-pay therapy shrinking |
| Retail entry | CVS $29 visit; Amazon One Medical $39 / $59; Walgreens $49 | Company announcements, 2026 | Price floor for a visit |
Funding: steady, but not for you
The headline is that digital health funding did not collapse. Rock Health's year-to-date total of $11.1 billion follows $7.4 billion in the first half across 244 deals, and the Q3 figure is a little above Q3 2025. We covered the first-half pattern in our H1 funding post: a small number of $100 million rounds, most of them for AI and enterprise infrastructure, took nearly half the money.
For a founder launching a cash-pay brand, venture funding is mostly irrelevant. The brands that work at small scale are funded by the founder, an angel or two, or a partner with an audience, and they need tens of thousands of dollars, not millions. That is a good thing. It means the funding cycle does not decide whether you can start.
Margins: the branded shift and the pharmacy question
Hims & Hers is the clearest data point. Second-quarter revenue grew 38% to $753.2 million, and the company guided Q3 to $880 million to $900 million. Gross margin fell to 64% from 76% a year earlier, because Hims now sells branded Wegovy and Ozempic through its own channel and books the drug at a thin margin. Growth bought with margin is still growth, and Hims had 2.9 million subscribers at the end of Q2.
LifeMD went the other way. Gross margin rose to about 89% on its in-house pharmacy and lower fulfilment costs, while revenue slipped to $47.3 million from $49.0 million, full-year revenue guidance was cut to $205.5 million to $212.5 million from $220 million to $230 million, and 95% of new weight-management patients started on branded drugs. Its weight-management subscribers grew to about 108,000.
BetterHelp is the warning. Teladoc reported BetterHelp revenue of $212.6 million in Q2, down 12%, and said cash-pay customers were leaving faster than expected while it builds insurance coverage. A cash-pay category can shrink, even with a famous brand.
What a small brand should take from this: do not try to profit on the drug. Let the manufacturer ship it at $349 for Wegovy or from $149 for the Wegovy pill, sell care and continuity as a membership, and protect contribution margin by keeping fixed costs flat. Our margin model shows a $149 membership keeping about 75% contribution on a flat-fee platform and about 52% to 58% on a 25% revenue share; the Q2 earnings takeaways cover the rest of the public set.
Exits: 164 so far, and what they imply
164 M&A deals in nine months is a lot of buyers. Rock Health does not break that number down by deal size or by DTC versus enterprise, and we will not guess at how many were small cash-pay brands. What we can say is that consolidation is happening, that a well-run brand with a few thousand retained patients has an audience of acquirers, and that what they will check is mostly decided on the day you pick your structure: whose merchant account, whose patient records, whose PC.
We think this is the most underrated reason to start a brand now rather than an affiliate funnel. An affiliate funnel has nothing to sell.
Retail: what $29 takes off the table
CVS launched a $29 MinuteClinic digital weight-loss visit with Lilly cash pricing and same-day pickup. Amazon One Medical charges $39 for messaging and $59 for video with no membership, with oral GLP-1 from $149. Walgreens charges $49 a visit in 28 states for branded drugs only. Those prices cap what anyone will pay for a single prescribing visit.
They do not cap what people pay for an ongoing program: titration, side-effect handling, nutrition, refill logistics, an HSA-ready receipt, a person who answers. That is where an independent brand prices, and it is why the $29 visit post argues for niche and retention over price.
Who should start one now
- A clinician (NP, PA, physician) with a following or a referral base who wants a cash-pay practice and does not want to build software.
- A founder with a defined patient group and a channel that does not depend on cold paid social: an employer relationship, a gym or med spa base, a creator audience, a benefits broker.
- A wellness or supplement brand that already has customers asking about prescription options.
- Anyone launching in a niche retail ignores: menopause and midlife hormones, hair, dermatology, maintenance programs after GLP-1 weight loss. The niches post has the economics.
Who should not
- Anyone whose plan is "GLP-1 at a lower price than the others." The $99 compounded price point is gone and the branded floor is set by the manufacturers.
- Founders who need venture-scale growth to justify the effort. The model works at hundreds of patients; it rarely produces the curve a seed fund wants.
- Programs built on controlled substances (testosterone, ADHD medication) that cannot run if the DEA telemedicine flexibilities lapse on December 31 without a final special registration rule. Wait for the rule.
- Anyone without six months of runway for acquisition. Our business plan template puts the illustrative cash low point at about $22,000 in a base case and about $50,000 if acquisition costs $400.
We would change our view if the FDA's 503B order or a payer shift moved GLP-1 pricing again, or if CVS and Amazon started bundling ongoing coaching at retail prices. Neither has happened yet.
Where the platform fits
The case for a brand in 2027 depends on fixed costs low enough that 50 patients cover them. That is what a white-label platform is for. Turbopills runs the storefront on your domain, conditional intake, state-aware provider routing, billing that starts after a provider approves, pharmacy routing with live status, a branded portal and mobile app, and an affiliate program for partner channels, with your own gateway accounts and your data readable through a GraphQL API. You still own the PC, the medical director, LegitScript and marketing. We are in private beta, quote per program and onboard by hand, so capacity is limited; verify the numbers against your own plan in a demo.
FAQ
Is telehealth still profitable in 2026? For cash-pay brands with flat fixed costs, yes: by our model a $149 membership program nets roughly $40,000 a month at 500 patients. Public companies show the range: Hims runs a 64% gross margin selling branded drugs, LifeMD about 89% with its own pharmacy.
How much did digital health raise in 2026? Rock Health counted $11.1 billion across 358 deals through Q3 2026, including $3.7 billion across 114 deals in Q3, per its October 12 report.
Is the telehealth market saturated? For generic GLP-1 prescriptions, largely yes: CVS, Amazon One Medical and Walgreens sell visits for $29 to $59. For specific patient groups and ongoing programs (menopause, maintenance, hair, dermatology, employer coverage loss), no.
How many digital health companies were acquired in 2026? Rock Health reported 45 M&A deals in Q3 2026 and 164 year to date as of its October 12 report.